TYPE,NAME,NODE_ID,source_primary,source_secondary,title,source_link,source_date,pubmed_id,country_of_origin
disease,dementia/parkinsonism with non-Alzheimer amyloid plaques,n_1,,,,,,,
disease,Alzheimer disease,n_2,,,,,,,
disease,"Alzheimer disease, familial early-onset, with coexisting amyloid and prion pathology",n_3,,,,,,,
disease,familial Alzheimer disease,n_4,,,,,,,
disease,Alzheimer disease without neurofibrillary tangles,n_5,,,,,,,
disease,"Alzheimer disease, susceptibility to, mitochondrial",n_6,,,,,,,
pathway,Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models,n_7,,,,,,,
Stage,Mild (MMSE 21-26),n_8,,,,,,,
Stage,Moderate (MMSE 10-20),n_9,,,,,,,
Stage,Severe (MMSE <10),n_10,,,,,,,
Treatment,Donepezil Treatment (NICE),n_11,,,,,,,
Treatment,Rivastigmine Treatment (NICE),n_12,,,,,,,
Treatment,Rivastigmine Patch Treatment (NICE),n_13,,,,,,,
Treatment,Galantamine Treatment (NICE),n_14,,,,,,,
Treatment,Galantamine Treatment moderate hepatic impairment (NICE),n_15,,,,,,,
Treatment,Memantine Treatment (NICE),n_16,,,,,,,
Treatment,Memantine Treatment renal impairment 1 (NICE),n_17,,,,,,,
Treatment,Memantine Treatment renal impairment 2 (NICE),n_18,,,,,,,
Treatment,Memantine Treatment renal impairment 3 (NICE),n_19,,,,,,,
Treatment,Haloperidol Treatment (NICE),n_20,,,,,,,
Treatment,Risperidone Treatment (NICE),n_21,,,,,,,
Step,Donepezil Treatment (NICE) (1),n_22,,,,,,,
Dosage,Donepezil 5mg/day,n_23,,,,,,,
Step,Donepezil Treatment (NICE) (2),n_24,,,,,,,
Step,Galantamine Treatment (NICE) (1),n_25,,,,,,,
Dosage,Galantamine 8mg/day,n_26,,,,,,,
Step,Galantamine Treatment (NICE) (2),n_27,,,,,,,
Dosage,Galantamine 16mg/day,n_28,,,,,,,
Step,Galantamine Treatment (NICE) (3),n_29,,,,,,,
Step,Galantamine Treatment moderate hepatic impairment (NICE) (1),n_30,,,,,,,
Step,Galantamine Treatment moderate hepatic impairment (NICE) (2),n_31,,,,,,,
Dosage,Galantamine 8-16mg/day,n_32,,,,,,,
Step,Rivastigmine Patch Treatment (NICE) (1),n_33,,,,,,,
Dosage,Rivastigmine Patch 4.6mg/day,n_34,,,,,,,
Step,Rivastigmine Patch Treatment (NICE) (2),n_35,,,,,,,
Dosage,Rivastigmine Patch 9.5mg/day,n_36,,,,,,,
Step,Rivastigmine Patch Treatment (NICE) (3),n_37,,,,,,,
Dosage,Risperidone 0.5-5 mg/day,n_38,,,,,,,
drug,Donepezil,n_39,,,,,,,
drug,Galantamine,n_40,,,,,,,
drug,Rivastigmine,n_41,,,,,,,
drug,Memantine,n_42,,,,,,,
drug,Haloperidol,n_43,,,,,,,
drug,Risperidone,n_44,,,,,,,
Therapy,Cognitive Stimulation Therapy,n_45,,,,,,,
Therapy,Reminiscence Therapy,n_46,,,,,,,
Therapy,Behavioral Management,n_47,,,,,,,
Therapy,Music Therapy,n_48,,,,,,,
Treatment,Donepezil Treatment (之),n_49,,,,,,,
Step,Donepezil Treatment (之) (1),n_50,,,,,,,
Step,Donepezil Treatment (之) (2),n_51,,,,,,,
Treatment,Rivastigmine Treatment (之),n_52,,,,,,,
Treatment,Galantamine Treatment (之),n_53,,,,,,,
Step,Galantamine Treatment (之) (1),n_54,,,,,,,
Step,Galantamine Treatment (之) (2),n_55,,,,,,,
Treatment,Memantine Treatment (之),n_56,,,,,,,
drug,Rivastigmine patch,n_57,,,,,,,
Stage,Mild  (ADAS-Cog),n_58,,,,,,,
Stage,Moderate (ADAS-Cog),n_59,,,,,,,
Stage,Severe (ADAS-Cog),n_60,,,,,,,
Treatment,Donepezil Treatment  (MaHTAS),n_61,,,,,,,
Treatment,Rivastigmine Patch Treatment (MaHTAS),n_62,,,,,,,
Treatment,Rivastigmine Treatment (MaHTAS),n_63,,,,,,,
Treatment,Galantamine Treatment (MaHTAS),n_64,,,,,,,
Treatment,Memantine Treatment (MaHTAS),n_65,,,,,,,
Treatment,Donepezil Treatment (MaHTAS),n_66,,,,,,,
Dosage,Donepezil 10 mg/day,n_67,,,,,,,
Dosage,Rivastigmine 6 - 12 mg/day*2,n_68,,,,,,,
Dosage,Rivastigmine Patch 9.5 mg/day,n_69,,,,,,,
drug,Rivastigmine Patch,n_70,,,,,,,
Therapy,Exercise,n_71,,,,,,,
Therapy,Diet and supplement,n_72,,,,,,,
Treatment,Donepezil Treatment (AmericanAcademy of Family Physicians),n_73,,,,,,,
Treatment,Rivastigmine Patch Treatment (AmericanAcademy of Family Physicians),n_74,,,,,,,
Treatment,Rivastigmine Treatment (AmericanAcademy of Family Physicians),n_75,,,,,,,
Treatment,Galantamine Immediate Release Treatment (AmericanAcademy of Family Physicians),n_76,,,,,,,
Treatment,Galantamine Extended Release Treatment (AmericanAcademy of Family Physicians),n_77,,,,,,,
Treatment,Memantine Immediate Release Treatment (AmericanAcademy of Family Physicians),n_78,,,,,,,
Treatment,Memantine Extended Release Treatment (AmericanAcademy of Family Physicians),n_79,,,,,,,
Treatment,Combination Drug and Vitamin E(AmericanAcademy of Family Physicians),n_80,,,,,,,
Step,Donepezil Treatment (AmericanAcademy of Family Physicians) (1),n_81,,,,,,,
Step,Donepezil Treatment (AmericanAcademy of Family Physicians) (2),n_82,,,,,,,
Step,Donepezil Treatment (AmericanAcademy of Family Physicians) (3),n_83,,,,,,,
Step,Rivastigmine Treatment (AmericanAcademy of Family Physicians) (1),n_84,,,,,,,
Dosage,Rivastigmine 1.5 mg/day*2,n_85,,,,,,,
Step,Rivastigmine Treatment (AmericanAcademy of Family Physicians) (2),n_86,,,,,,,
Dosage,Rivastigmine 3 mg/day*2,n_87,,,,,,,
Step,Rivastigmine Treatment (AmericanAcademy of Family Physicians) (3),n_88,,,,,,,
Dosage,Rivastigmine 4.5 mg/day*2,n_89,,,,,,,
Step,Rivastigmine Patch Treatment (AmericanAcademy of Family Physicians) (1),n_90,,,,,,,
Dosage,Rivastigmine Patch Treatment (AmericanAcademy of Family Physicians) (1),n_91,,,,,,,
Step,Rivastigmine Patch Treatment (AmericanAcademy of Family Physicians) (2),n_92,,,,,,,
Dosage,Rivastigmine Patch Treatment (AmericanAcademy of Family Physicians) (2),n_93,,,,,,,
Step,Rivastigmine Patch Treatment (AmericanAcademy of Family Physicians) (3),n_94,,,,,,,
Step,Galantamine Immediate Release Treatment (AmericanAcademy of Family Physicians) (1),n_95,,,,,,,
Dosage,Galantamine Immediate Release Treatment (AmericanAcademy of Family Physicians) (1),n_96,,,,,,,
Step,Galantamine Immediate Release Treatment (AmericanAcademy of Family Physicians) (2),n_97,,,,,,,
Dosage,Galantamine 8 mg/day*2,n_98,,,,,,,
Step,Galantamine Immediate Release Treatment (AmericanAcademy of Family Physicians) (3),n_99,,,,,,,
Step,Galantamine Extended Release Treatment (AmericanAcademy of Family Physicians) (1),n_100,,,,,,,
Dosage,Galantamine 8 mg/day,n_101,,,,,,,
Step,Galantamine Extended Release Treatment (AmericanAcademy of Family Physicians) (2),n_102,,,,,,,
Step,Galantamine Extended Release Treatment (AmericanAcademy of Family Physicians) (3),n_103,,,,,,,
Step,Memantine Immediate Release Treatment (AmericanAcademy of Family Physicians) (1),n_104,,,,,,,
Dosage,Memantine 5mg/day,n_105,,,,,,,
Step,Memantine Immediate Release Treatment (AmericanAcademy of Family Physicians) (2),n_106,,,,,,,
Dosage,Memantine 5mg/day*2,n_107,,,,,,,
Dosage,Memantine 10mg/day,n_108,,,,,,,
Step,Memantine Immediate Release Treatment (AmericanAcademy of Family Physicians) (3),n_109,,,,,,,
Step,Memantine Immediate Release Treatment (AmericanAcademy of Family Physicians) (4),n_110,,,,,,,
Step,Memantine Extended Release Treatment (AmericanAcademy of Family Physicians) (1),n_111,,,,,,,
Dosage,Memantine 7 mg/day,n_112,,,,,,,
Step,Memantine Extended Release Treatment (AmericanAcademy of Family Physicians) (2),n_113,,,,,,,
Dosage,Memantine 14 mg/day,n_114,,,,,,,
Step,Memantine Extended Release Treatment (AmericanAcademy of Family Physicians) (3),n_115,,,,,,,
Step,Memantine Extended Release Treatment (AmericanAcademy of Family Physicians) (4),n_116,,,,,,,
Dosage,Memantine 21 mg/day,n_117,,,,,,,
Step,Memantine Extended Release Treatment (AmericanAcademy of Family Physicians) (5),n_118,,,,,,,
Step,Combination Drug and Vitamin E(AmericanAcademy of Family Physicians) (1),n_119,,,,,,,
Dosage,Donepezil 10mg/day,n_120,,,,,,,
Dosage,"Vitamin E 1,000IU/day*2",n_121,,,,,,,
Step,Combination Drug and Vitamin E(AmericanAcademy of Family Physicians) (2),n_122,,,,,,,
Step,Combination Drug and Vitamin E(AmericanAcademy of Family Physicians) (3),n_123,,,,,,,
Step,Combination Drug and Vitamin E(AmericanAcademy of Family Physicians) (4),n_124,,,,,,,
Step,Combination Drug and Vitamin E(AmericanAcademy of Family Physicians) (5),n_125,,,,,,,
drug,Vitamin E,n_126,,,,,,,
Therapy,Enjoyable leisure activities,n_127,,,,,,,
Therapy,Mental stimulation programs,n_128,,,,,,,
Therapy,Occupational therapy training in coping strategies and cognitive aides,n_129,,,,,,,
Therapy,Structured physical exercise programs,n_130,,,,,,,
Stage,拇,n_131,,,,,,,
Stage,銝剜,n_132,,,,,,,
Stage,,n_133,,,,,,,
Treatment,Donepezil Treatment (箔葉璁桃蜇),n_134,,,,,,,
Step,Donepezil Treatment (箔葉璁桃蜇) (1),n_135,,,,,,,
Dosage,Donepezil 5 mg/day,n_136,,,,,,,
Step,Donepezil Treatment (箔葉璁桃蜇) (2),n_137,,,,,,,
Treatment,Rivastigmine Treatment (箔葉璁桃蜇),n_138,,,,,,,
Step,Rivastigmine Treatment (箔葉璁桃蜇) (1),n_139,,,,,,,
Dosage,Rivastigmine 1.5 mg/day,n_140,,,,,,,
Step,Rivastigmine Treatment (箔葉璁桃蜇) (2),n_141,,,,,,,
Step,Rivastigmine Treatment (箔葉璁桃蜇) (3),n_142,,,,,,,
Treatment,Rivastigmine Patch Treatment (箔葉璁桃蜇),n_143,,,,,,,
Step,Rivastigmine Patch Treatment (箔葉璁桃蜇) (1),n_144,,,,,,,
Dosage,Rivastigmine Patch 4.6 mg/day,n_145,,,,,,,
Step,Rivastigmine Patch Treatment (箔葉璁桃蜇) (2),n_146,,,,,,,
Treatment,Galantamine Treatment (箔葉璁桃蜇),n_147,,,,,,,
Step,Galantamine Treatment (箔葉璁桃蜇) (1),n_148,,,,,,,
Step,Galantamine Treatment (箔葉璁桃蜇) (2),n_149,,,,,,,
Treatment,Memantine Treatment (箔葉璁桃蜇),n_150,,,,,,,
Step,Memantine Treatment (箔葉璁桃蜇) (1),n_151,,,,,,,
Step,Memantine Treatment (箔葉璁桃蜇) (2),n_152,,,,,,,
Treatment,Memantine Treatment 賭雿唾 (箔葉璁桃蜇),n_153,,,,,,,
Step,Memantine Treatment 賭雿唾 (箔葉璁桃蜇),n_154,,,,,,,
Therapy,Cognitive Activities,n_155,,,,,,,
Therapy,Music Therapy Groups,n_156,,,,,,,
Therapy,Art Creation,n_157,,,,,,,
Therapy,Exercise Groups,n_158,,,,,,,
Therapy,Reality Orientation Therapy,n_159,,,,,,,
Therapy,Dance Therapy,n_160,,,,,,,
Therapy,Horticulture Therapy,n_161,,,,,,,
Therapy,Aromatherapy,n_162,,,,,,,
Therapy,Pet Therapy,n_163,,,,,,,
Therapy,Doll Therapy,n_164,,,,,,,
Therapy,Sensory Stimulation,n_165,,,,,,,
Stage,Early stage(GDS 2-5),n_166,,,,,,,
Stage,Middle stage (GDS 4-6),n_167,,,,,,,
Stage,Late stage (GDS 7),n_168,,,,,,,
Treatment,Combined Donepezil and Memantine Treatment (Japanese Society of Neurology),n_169,,,,,,,
Treatment,Donepezil Treatment (Japanese Society of Neurology),n_170,,,,,,,
Treatment,Galantamine Treatment (Japanese Society of Neurology),n_171,,,,,,,
Treatment,Rivastigmine Treatment (Japanese Society of Neurology),n_172,,,,,,,
Treatment,Rivastigmine Patch Treatment (Japanese Society of Neurology),n_173,,,,,,,
Treatment,Memantine Treatment (Japanese Society of Neurology),n_174,,,,,,,
Treatment,Combined ChEIs and Memantine Treatment (Japanese Society of Neurology),n_175,,,,,,,
Therapy,Exercise therapy,n_176,,,,,,,
Therapy,Music therapy,n_177,,,,,,,
Stage,(MCI) due to Alzheimer's disease,n_178,,,,,,,
Stage,Early stage(mild),n_179,,,,,,,
Stage,Middle stage (moderate),n_180,,,,,,,
Stage,Late stage (severe),n_181,,,,,,,
Stage,MCI due to Alzheimer's disease,n_182,,,,,,,
Treatment,Donanemab Treatment (Alzheimer's Association),n_183,,,,,,,
Treatment,Lecanemab (Alzheimer's Association),n_184,,,,,,,
Treatment,Donepezil Treatment (Alzheimer's Association),n_185,,,,,,,
Treatment,Rivastigmine Treatment (Alzheimer's Association),n_186,,,,,,,
Treatment,Galantamine Treatment (Alzheimer's Association),n_187,,,,,,,
Treatment,Memantine Treatment (Alzheimer's Association),n_188,,,,,,,
Treatment,Memantine + Donepezil (Alzheimer's Association),n_189,,,,,,,
Treatment,Brexpiprazole Treatment (Alzheimer's Association),n_190,,,,,,,
Treatment,Suvorexant Treatment (Alzheimer's Association),n_191,,,,,,,
drug,Donanemab,n_192,,,,,,,
drug,Lecanemab,n_193,,,,,,,
drug,Brexpiprazole,n_194,,,,,,,
drug,Suvorexant,n_195,,,,,,,
Treatment,Donepezil Treatment (Demenzen),n_196,,,,,,,
Treatment,Rivastigmine Treatment (Demenzen),n_197,,,,,,,
Treatment,Galantamine Treatment (Demenzen),n_198,,,,,,,
Treatment,Memantine Treatment (Demenzen),n_199,,,,,,,
Dosage,Rivastigmine 3mg/day,n_200,,,,,,,
Treatment,Donepezil Treatment (CDPC),n_201,,,,,,,
Treatment,Rivastigmine Treatment (CDPC),n_202,,,,,,,
Treatment,Galantamine Treatment (CDPC),n_203,,,,,,,
Treatment,Memantine Treatment (CDPC),n_204,,,,,,,
Dosage,Galantamine 5mg/day,n_205,,,,,,,
Dosage,Rivastigmine 5mg/day,n_206,,,,,,,
effect/phenotype,Parkinsonism,n_207,,,,,,,
effect/phenotype,Dementia,n_208,,,,,,,
effect/phenotype,Substantia nigra gliosis,n_209,,,,,,,
effect/phenotype,Autosomal dominant inheritance,n_210,,,,,,,
effect/phenotype,Dysphagia,n_211,,,,,,,
effect/phenotype,Optic ataxia,n_212,,,,,,,
effect/phenotype,Gait disturbance,n_213,,,,,,,
effect/phenotype,Memory impairment,n_214,,,,,,,
effect/phenotype,Babinski sign,n_215,,,,,,,
effect/phenotype,Seizure,n_216,,,,,,,
effect/phenotype,Cerebral cortical atrophy,n_217,,,,,,,
effect/phenotype,Apraxia,n_218,,,,,,,
effect/phenotype,Lower limb hyperreflexia,n_219,,,,,,,
effect/phenotype,Dysarthria,n_220,,,,,,,
effect/phenotype,Spastic tetraparesis,n_221,,,,,,,
effect/phenotype,Adult onset,n_222,,,,,,,
effect/phenotype,Neurofibrillary tangles,n_223,,,,,,,
effect/phenotype,Abnormality of extrapyramidal motor function,n_224,,,,,,,
effect/phenotype,Agnosia,n_225,,,,,,,
effect/phenotype,Personality changes,n_226,,,,,,,
effect/phenotype,Myoclonus,n_227,,,,,,,
effect/phenotype,Rapidly progressive,n_228,,,,,,,
effect/phenotype,Decreased level of GABA in serum,n_229,,,,,,,
effect/phenotype,Long-tract signs,n_230,,,,,,,
effect/phenotype,Heterogeneous,n_231,,,,,,,
effect/phenotype,Sleep-wake cycle disturbance,n_232,,,,,,,
effect/phenotype,Middle age onset,n_233,,,,,,,
effect/phenotype,Cognitive impairment,n_234,,,,,,,
effect/phenotype,Parietal hypometabolism in FDG PET,n_235,,,,,,,
effect/phenotype,Cerebral amyloid angiopathy,n_236,,,,,,,
effect/phenotype,Senile plaques,n_237,,,,,,,
effect/phenotype,Depressivity,n_238,,,,,,,
effect/phenotype,Disinhibition,n_239,,,,,,,
effect/phenotype,Hippocampal atrophy,n_240,,,,,,,
effect/phenotype,Late onset,n_241,,,,,,,
effect/phenotype,Neurological speech impairment,n_242,,,,,,,
effect/phenotype,Cerebral cortex with spongiform changes,n_243,,,,,,,
effect/phenotype,Behavioral abnormality,n_244,,,,,,,
effect/phenotype,Emotional lability,n_245,,,,,,,
effect/phenotype,Anxiety,n_246,,,,,,,
effect/phenotype,Specific learning disability,n_247,,,,,,,
effect/phenotype,Sleep disturbance,n_248,,,,,,,
effect/phenotype,Deficit in phonologic short-term memory,n_249,,,,,,,
effect/phenotype,Attention deficit hyperactivity disorder,n_250,,,,,,,
effect/phenotype,Abdominal symptom,n_251,,,,,,,
effect/phenotype,Perseveration,n_252,,,,,,,
effect/phenotype,Jaw pain,n_253,,,,,,,
effect/phenotype,Agitation,n_254,,,,,,,
effect/phenotype,Hallucinations,n_255,,,,,,,
effect/phenotype,Hypertonia,n_256,,,,,,,
effect/phenotype,Confusion,n_257,,,,,,,
effect/phenotype,Deposits immunoreactive to beta-amyloid protein,n_258,,,,,,,
effect/phenotype,Abnormal social behavior,n_259,,,,,,,
effect/phenotype,Neurodevelopmental abnormality,n_260,,,,,,,
effect/phenotype,Abnormality of vision,n_261,,,,,,,
effect/phenotype,Oculomotor apraxia,n_262,,,,,,,
effect/phenotype,Intellectual disability,n_263,,,,,,,
effect/phenotype,Ataxia,n_264,,,,,,,
effect/phenotype,Aphasia,n_265,,,,,,,
effect/phenotype,Abnormality of higher mental function,n_266,,,,,,,
effect/phenotype,Semantic dementia,n_267,,,,,,,
drug,Phenyltoloxamine,n_268,,,,,,,
drug,Pheniramine,n_269,,,,,,,
drug,Orphenadrine,n_270,,,,,,,
drug,Pravastatin,n_271,,,,,,,
drug,Carisoprodol,n_272,,,,,,,
drug,Citric acid,n_273,,,,,,,
drug,Butalbital,n_274,,,,,,,
drug,Codeine,n_275,,,,,,,
drug,Oxycodone,n_276,,,,,,,
drug,Trolnitrate,n_277,,,,,,,
drug,Salicylamide,n_278,,,,,,,
drug,Phenacetin,n_279,,,,,,,
drug,Phenylephrine,n_280,,,,,,,
drug,Dipyridamole,n_281,,,,,,,
drug,Caffeine,n_282,,,,,,,
drug,Meprobamate,n_283,,,,,,,
drug,Methocarbamol,n_284,,,,,,,
drug,Phenobarbital,n_285,,,,,,,
drug,Dextropropoxyphene,n_286,,,,,,,
drug,Pentazocine,n_287,,,,,,,
drug,Calcium gluconate,n_288,,,,,,,
drug,Phenylpropanolamine,n_289,,,,,,,
drug,Chlorpheniramine,n_290,,,,,,,
drug,Hydrocodone,n_291,,,,,,,
drug,Dihydrocodeine,n_292,,,,,,,
drug,Epicriptine,n_293,,,,,,,
drug,Perazine,n_294,,,,,,,
drug,Alimemazine,n_295,,,,,,,
drug,Isopropamide,n_296,,,,,,,
drug,Molindone,n_297,,,,,,,
drug,Fluphenazine,n_298,,,,,,,
drug,Pramiracetam,n_299,,,,,,,
drug,Methotrimeprazine,n_300,,,,,,,
drug,Promazine,n_301,,,,,,,
drug,Perphenazine,n_302,,,,,,,
drug,Prochlorperazine,n_303,,,,,,,
drug,Clozapine,n_304,,,,,,,
drug,Fluoxetine,n_305,,,,,,,
drug,Chlorpromazine,n_306,,,,,,,
drug,Thioridazine,n_307,,,,,,,
drug,Amitriptyline,n_308,,,,,,,
drug,Propiomazine,n_309,,,,,,,
drug,Thiothixene,n_310,,,,,,,
drug,Acetylcarnitine,n_311,,,,,,,
drug,Acetophenazine,n_312,,,,,,,
drug,Pimozide,n_313,,,,,,,
drug,Loxapine,n_314,,,,,,,
drug,Ziprasidone,n_315,,,,,,,
drug,Triflupromazine,n_316,,,,,,,
drug,Paliperidone,n_317,,,,,,,
drug,Iloperidone,n_318,,,,,,,
drug,Olanzapine,n_319,,,,,,,
drug,Aripiprazole,n_320,,,,,,,
drug,Trifluoperazine,n_321,,,,,,,
drug,Chlorprothixene,n_322,,,,,,,
drug,Quetiapine,n_323,,,,,,,
drug,Asenapine,n_324,,,,,,,
drug,Ipidacrine,n_325,,,,,,,
drug,Tacrine,n_326,,,,,,,
effect/phenotype,Morphological central nervous system abnormality,n_327,,,,,,,
gene/protein,A2M,n_328,,,,,,,
gene/protein,ACHE,n_329,,,,,,,
gene/protein,ADAM10,n_330,,,,,,,
gene/protein,AMFR,n_331,,,,,,,
gene/protein,BIN1,n_332,,,,,,,
gene/protein,APOC1,n_333,,,,,,,
gene/protein,APOE,n_334,,,,,,,
gene/protein,APP,n_335,,,,,,,
gene/protein,ATP5F1A,n_336,,,,,,,
gene/protein,BAX,n_337,,,,,,,
gene/protein,BCHE,n_338,,,,,,,
gene/protein,BCL2,n_339,,,,,,,
gene/protein,BDNF,n_340,,,,,,,
gene/protein,CALM1,n_341,,,,,,,
gene/protein,CASP3,n_342,,,,,,,
gene/protein,CD33,n_343,,,,,,,
gene/protein,CHRNA7,n_344,,,,,,,
gene/protein,CHRNB2,n_345,,,,,,,
gene/protein,CLU,n_346,,,,,,,
gene/protein,TPP1,n_347,,,,,,,
gene/protein,CR1,n_348,,,,,,,
gene/protein,CRH,n_349,,,,,,,
gene/protein,CST3,n_350,,,,,,,
gene/protein,CYP2D6,n_351,,,,,,,
gene/protein,ACE,n_352,,,,,,,
gene/protein,DHCR24,n_353,,,,,,,
gene/protein,DPYSL2,n_354,,,,,,,
gene/protein,EIF2S1,n_355,,,,,,,
gene/protein,ENO1,n_356,,,,,,,
gene/protein,EPHA1,n_357,,,,,,,
gene/protein,ESR1,n_358,,,,,,,
gene/protein,F2,n_359,,,,,,,
gene/protein,GSK3B,n_360,,,,,,,
gene/protein,HFE,n_361,,,,,,,
gene/protein,HLA-DRB5,n_362,,,,,,,
gene/protein,HMOX1,n_363,,,,,,,
gene/protein,IDE,n_364,,,,,,,
gene/protein,IGF1,n_365,,,,,,,
gene/protein,IGF1R,n_366,,,,,,,
gene/protein,IGF2,n_367,,,,,,,
gene/protein,IGF2R,n_368,,,,,,,
gene/protein,IL1B,n_369,,,,,,,
gene/protein,INS,n_370,,,,,,,
gene/protein,INPP5D,n_371,,,,,,,
gene/protein,INSR,n_372,,,,,,,
gene/protein,LEP,n_373,,,,,,,
gene/protein,MAOB,n_374,,,,,,,
gene/protein,MAPT,n_375,,,,,,,
gene/protein,MPO,n_376,,,,,,,
gene/protein,MTHFR,n_377,,,,,,,
gene/protein,NOS3,n_378,,,,,,,
gene/protein,NPY,n_379,,,,,,,
gene/protein,PLAU,n_380,,,,,,,
gene/protein,PLCG2,n_381,,,,,,,
gene/protein,PPARG,n_382,,,,,,,
gene/protein,PRNP,n_383,,,,,,,
gene/protein,RELN,n_384,,,,,,,
gene/protein,PSEN1,n_385,,,,,,,
gene/protein,PSEN2,n_386,,,,,,,
gene/protein,PYY,n_387,,,,,,,
gene/protein,NECTIN2,n_388,,,,,,,
gene/protein,SLC2A4,n_389,,,,,,,
gene/protein,SOD2,n_390,,,,,,,
gene/protein,SORL1,n_391,,,,,,,
gene/protein,TF,n_392,,,,,,,
gene/protein,TFAM,n_393,,,,,,,
gene/protein,TNF,n_394,,,,,,,
gene/protein,TPI1,n_395,,,,,,,
gene/protein,VEGFA,n_396,,,,,,,
gene/protein,VSNL1,n_397,,,,,,,
gene/protein,SLC30A4,n_398,,,,,,,
gene/protein,PICALM,n_399,,,,,,,
gene/protein,UNC5C,n_400,,,,,,,
gene/protein,ADAMTS1,n_401,,,,,,,
gene/protein,ABCA7,n_402,,,,,,,
gene/protein,TOMM40,n_403,,,,,,,
gene/protein,PGRMC1,n_404,,,,,,,
gene/protein,CYP46A1,n_405,,,,,,,
gene/protein,ARC,n_406,,,,,,,
gene/protein,NCSTN,n_407,,,,,,,
gene/protein,CD2AP,n_408,,,,,,,
gene/protein,BACE1,n_409,,,,,,,
gene/protein,GAPDHS,n_410,,,,,,,
gene/protein,PCDH11X,n_411,,,,,,,
gene/protein,ABI3,n_412,,,,,,,
gene/protein,MS4A4A,n_413,,,,,,,
gene/protein,WWOX,n_414,,,,,,,
gene/protein,TREM2,n_415,,,,,,,
gene/protein,SLC30A6,n_416,,,,,,,
gene/protein,CASS4,n_417,,,,,,,
gene/protein,IQCK,n_418,,,,,,,
gene/protein,MIR100,n_419,,,,,,,
gene/protein,MIR146A,n_420,,,,,,,
gene/protein,MIR296,n_421,,,,,,,
gene/protein,MIR375,n_422,,,,,,,
gene/protein,MIR505,n_423,,,,,,,
gene/protein,MIR766,n_424,,,,,,,
gene/protein,MIR708,n_425,,,,,,,
gene/protein,SNAR-I,n_426,,,,,,,
gene/protein,MIR3622B,n_427,,,,,,,
gene/protein,MIR4467,n_428,,,,,,,
gene/protein,ND1,n_429,,,,,,,
gene/protein,ND2,n_430,,,,,,,
disease,tauopathy,n_431,,,,,,,
disease,dementia (disease),n_432,,,,,,,
disease,Mendelian disease,n_433,,,,,,,
disease,inherited disease susceptibility,n_434,,,,,,,
disease,autosomal dominant disease,n_435,,,,,,,
disease,inherited neurodegenerative disorder,n_436,,,,,,,
disease,genetic dementia,n_437,,,,,,,
disease,inherited prion disease,n_438,,,,,,,
exposure,Aluminum,n_439,,,,,,,
exposure,Cadmium,n_440,,,,,,,
exposure,Metals,n_441,,,,,,,
exposure,Nitrogen Oxides,n_442,,,,,,,
exposure,Ozone,n_443,,,,,,,
exposure,Particulate Matter,n_444,,,,,,,
exposure,Pesticides,n_445,,,,,,,
exposure,Silicon Dioxide,n_446,,,,,,,
pathway,Neurodegenerative Diseases,n_447,,,,,,,
gene/protein,BCL2L11,n_448,,,,,,,
gene/protein,CDK5,n_449,,,,,,,
gene/protein,FOXO3,n_450,,,,,,,
gene/protein,GOLGA2,n_451,,,,,,,
gene/protein,FASLG,n_452,,,,,,,
gene/protein,JUN,n_453,,,,,,,
gene/protein,LMNA,n_454,,,,,,,
gene/protein,LMNB1,n_455,,,,,,,
gene/protein,PRDX1,n_456,,,,,,,
gene/protein,PRDX2,n_457,,,,,,,
gene/protein,YWHAE,n_458,,,,,,,
gene/protein,CAPN1,n_459,,,,,,,
gene/protein,CAPN2,n_460,,,,,,,
gene/protein,CAPNS1,n_461,,,,,,,
gene/protein,CAST,n_462,,,,,,,
gene/protein,CAPNS2,n_463,,,,,,,
gene/protein,CDK5R1,n_464,,,,,,,
gene/protein,CDC25A,n_465,,,,,,,
gene/protein,CDC25B,n_466,,,,,,,
gene/protein,CDC25C,n_467,,,,,,,
Phenotypes,Memory loss for recent events,n_468,,,,,,,
Phenotypes,Difficulty learning new information,n_469,,,,,,,
Phenotypes,Subtle language problems,n_470,,,,,,,
Phenotypes,Significant memory loss,n_471,,,,,,,
Phenotypes,Confusion in daily activities,n_472,,,,,,,
Phenotypes,Behavioral changes,n_473,,,,,,,
Phenotypes,Severe memory loss,n_474,,,,,,,
Phenotypes,Complete dependence on others,n_475,,,,,,,
Phenotypes,Physical symptoms,n_476,,,,,,,
Evidence,High quality (Level A),n_477,,,,,,,
Evidence,Moderate quality (Level B),n_478,,,,,,,
Duration,1 month,n_479,,,,,,,
Population,increased if tolerated and necessary,n_480,,,,,,,
Effectiveness,Significant improvement in cognitive scores and daily activities,n_481,,,,,,,
Population,Mild to Severe Alzheimer's Disease (MMSE 0-26),n_482,,,,,,,
Duration,4 week,n_483,,,,,,,
Duration,least 4 week,n_484,,,,,,,
Dosage,Galantamine 16-24mg/day,n_485,,,,,,,
Population,Mild to moderate Alzheimer's Disease (MMSE 0-26),n_486,,,,,,,
Duration,1 week,n_487,,,,,,,
Population,moderate hepatic impairment,n_488,,,,,,,
Dosage,Rivastigmine 1.5-6.0 twice daily,n_489,,,,,,,
Duration,6 week,n_490,,,,,,,
Dosage,Rivastigmine Patch 13.3mg/day,n_491,,,,,,,
Dosage,Memantine 5-20 mg/day,n_492,,,,,,,
Effectiveness,Significant improvement in cognitive decline and behavioral symptoms,n_493,,,,,,,
Population,Moderate to severe Alzheimer's Disease (MMSE < 20),n_494,,,,,,,
Dosage,Memantine 10-20 mg/day,n_495,,,,,,,
Population,eGFR is 3049 mL/minute/1.73 m簡,n_496,,,,,,,
Dosage,Memantine 10 mg/day,n_497,,,,,,,
Population,eGFR is 5 - 29 mL/minute/1.73 m簡,n_498,,,,,,,
Dosage,Haloperidol 0.5-5 mg/day,n_499,,,,,,,
Duration,no more than 6 weeks,n_500,,,,,,,
SideEffect,Nausea,n_501,,,,,,,
SideEffect,Vomiting,n_502,,,,,,,
SideEffect,Anorexia,n_503,,,,,,,
SideEffect,Diarrhea,n_504,,,,,,,
SideEffect,Muscle cramps,n_505,,,,,,,
SideEffect,Syncope,n_506,,,,,,,
SideEffect,Headache,n_507,,,,,,,
SideEffect,Dizziness,n_508,,,,,,,
SideEffect,Abnormal dreams,n_509,,,,,,,
SideEffect,Hallucinations,n_510,,,,,,,
SideEffect,Agitation,n_511,,,,,,,
SideEffect,Aggression,n_512,,,,,,,
SideEffect,Urinary incontinence,n_513,,,,,,,
SideEffect,Rash,n_514,,,,,,,
SideEffect,Pruritus,n_515,,,,,,,
SideEffect,Extrapyramidal symptoms,n_516,,,,,,,
SideEffect,Sinoatrial block,n_517,,,,,,,
SideEffect,Atrioventricular (AV) block,n_518,,,,,,,
SideEffect,Liver dysfunction (including hepatitis),n_519,,,,,,,
SideEffect,Neuroleptic malignant syndrome (NMS),n_520,,,,,,,
SideEffect,Fatigue,n_521,,,,,,,
SideEffect,Insomnia,n_522,,,,,,,
SideEffect,Abdominal pain,n_523,,,,,,,
SideEffect,Diarrhoea,n_524,,,,,,,
SideEffect,Dyspepsia,n_525,,,,,,,
SideEffect,Decreased appetite,n_526,,,,,,,
SideEffect,Weight loss ,n_527,,,,,,,
SideEffect,Bradycardia,n_528,,,,,,,
SideEffect,Hypertension,n_529,,,,,,,
SideEffect,Depression,n_530,,,,,,,
SideEffect,Tremor,n_531,,,,,,,
SideEffect,Malaise,n_532,,,,,,,
SideEffect,Muscle spasm,n_533,,,,,,,
SideEffect,Retching,n_534,,,,,,,
SideEffect,Dehydration,n_535,,,,,,,
SideEffect,Hypotension,n_536,,,,,,,
SideEffect,Flushing,n_537,,,,,,,
SideEffect,Palpitation,n_538,,,,,,,
SideEffect,Arrhythmias,n_539,,,,,,,
SideEffect,First-degree AV block,n_540,,,,,,,
SideEffect,Taste disturbance,n_541,,,,,,,
SideEffect,Paraesthesia,n_542,,,,,,,
SideEffect,Seizures,n_543,,,,,,,
SideEffect,Hypersomnia,n_544,,,,,,,
SideEffect,Muscular weakness,n_545,,,,,,,
SideEffect,Blurred vision,n_546,,,,,,,
SideEffect,Tinnitus,n_547,,,,,,,
SideEffect,Sweating,n_548,,,,,,,
SideEffect,Exacerbation of Parkinson's disease,n_549,,,,,,,
SideEffect,Hepatitis,n_550,,,,,,,
SideEffect,Serious skin reactions,n_551,,,,,,,
SideEffect,Weight loss,n_552,,,,,,,
SideEffect,Drowsiness,n_553,,,,,,,
SideEffect,Gait abnormalities,n_554,,,,,,,
SideEffect,Fall,n_555,,,,,,,
SideEffect,Anxiety,n_556,,,,,,,
SideEffect,Confusion,n_557,,,,,,,
SideEffect,Parkinsonism,n_558,,,,,,,
SideEffect,Skin reactions,n_559,,,,,,,
SideEffect,Urinary tract infection,n_560,,,,,,,
SideEffect,Atrial fibrillation,n_561,,,,,,,
SideEffect,AV block,n_562,,,,,,,
SideEffect,Gastric and duodenal ulceration,n_563,,,,,,,
SideEffect,Pancreatitis,n_564,,,,,,,
SideEffect,Angina,n_565,,,,,,,
SideEffect,Restlessness,n_566,,,,,,,
SideEffect,Sick sinus syndrome,n_567,,,,,,,
SideEffect,Tachycardia,n_568,,,,,,,
SideEffect,Constipation,n_569,,,,,,,
SideEffect,Dyspnoea,n_570,,,,,,,
SideEffect,Impaired balance,n_571,,,,,,,
SideEffect,Thrombosis,n_572,,,,,,,
SideEffect,Heart failure,n_573,,,,,,,
SideEffect,Abnormal gait,n_574,,,,,,,
SideEffect,Psychosis,n_575,,,,,,,
SideEffect,Suicidal ideation,n_576,,,,,,,
SideEffect,Weight gain,n_577,,,,,,,
SideEffect,Dyslipidaemia,n_578,,,,,,,
SideEffect,Hyperprolactinaemia,n_579,,,,,,,
SideEffect,Sedation,n_580,,,,,,,
SideEffect,Sleep apnoea syndrome,n_581,,,,,,,
SideEffect,Anticholinergic effects,n_582,,,,,,,
SideEffect,Postural hypotension,n_583,,,,,,,
SideEffect,Reduced seizure threshold,n_584,,,,,,,
SideEffect,Impaired glucose tolerance,n_585,,,,,,,
SideEffect,"Cardiomyopathy, myocarditis, and cutaneous vasculitis",n_586,,,,,,,
SideEffect,QT interval prolongation,n_587,,,,,,,
SideEffect,Stroke risk,n_588,,,,,,,
SideEffect,Venous thromboembolism (VTE),n_589,,,,,,,
SideEffect,Pneumonia,n_590,,,,,,,
SideEffect,Neutropenia,n_591,,,,,,,
SideEffect,Abnormal liver function tests (LFTs),n_592,,,,,,,
SideEffect,Photosensitivity,n_593,,,,,,,
SideEffect,Skin and subcutaneous tissue disorders,n_594,,,,,,,
SideEffect,Diplopia,n_595,,,,,,,
SideEffect,Misuse and abuse,n_596,,,,,,,
SideEffect,Restless legs syndrome,n_597,,,,,,,
Effectiveness,Improves memory attention and social interaction,n_598,,,,,,,
Effectiveness,Helps maintain long-term memory improves mood,n_599,,,,,,,
Effectiveness,Reduces anxiety and agitation improves daily functioning,n_600,,,,,,,
Effectiveness,Improves mood reduces agitation provides positive emotions,n_601,,,,,,,
Phenotypes,Severe cardiac arrhythmia,n_602,,,,,,,
Phenotypes,Pregnancy and breastfeeding.,n_603,,,,,,,
Phenotypes,"Known hypersensitivity to donepezil hydrochloride, piperidine derivatives, or any excipients used in the formulation",n_604,,,,,,,
Phenotypes,"History of bradycardia, heart block, recurrent unexplained syncope.",n_605,,,,,,,
Phenotypes,Concurrent treatment with drugs that reduce heart rate.,n_606,,,,,,,
Phenotypes,Sick sinus syndrome or other supraventricular conduction abnormalities.,n_607,,,,,,,
Phenotypes,Susceptibility to peptic ulcers including concurrent nonsteroidalanti inflammatory(NSAID) use.,n_608,,,,,,,
Phenotypes,Asthma and chronic obstructive pulmonary disease (COPD).,n_609,,,,,,,
Phenotypes,Hepatic impairment.,n_610,,,,,,,
Phenotypes,Concomitant antipsychotic treatment  increased risk of neuroleptic malignant syndrome (NMS).,n_611,,,,,,,
Phenotypes,Hypersensitivity to galantamine or to any of the excipients.,n_612,,,,,,,
Phenotypes,Severe renal impairment (estimated glomerular filtration rate [eGFR] less than 9 mL/minute/1.73 m簡).,n_613,,,,,,,
Phenotypes,Severe hepatic impairment (Child-Pugh score greater than 9).,n_614,,,,,,,
Phenotypes,People who have both significant renal and hepatic dysfunction.,n_615,,,,,,,
Phenotypes,Urinary outflow obstruction.,n_616,,,,,,,
Phenotypes,Gastrointestinal obstruction.,n_617,,,,,,,
Phenotypes,During recovery from bladder or gastrointestinal surgery.,n_618,,,,,,,
Phenotypes,Renal and hepatic impairment.,n_619,,,,,,,
Phenotypes,"Cardiac disease or in those who use medicinal products that significantly reduce heart rate concomitantly, such as digoxin and beta blockers.",n_620,,,,,,,
Phenotypes,QTc interval prolongation or taking drugs that prolong the QTc interval.,n_621,,,,,,,
Phenotypes,Electrolyte disturbances (such as hyperkalaemia or hypokalaemia).,n_622,,,,,,,
Phenotypes,"Susceptibility to peptic ulcers, including concomitant use of NSAIDs.",n_623,,,,,,,
Phenotypes,"History of severe asthma, COPD, or pulmonary infection.",n_624,,,,,,,
Phenotypes,History of seizures.,n_625,,,,,,,
Phenotypes,"Known hypersensitivity to rivastigmine, other carbamate derivatives, or to any of the excipients used in the formulation.",n_626,,,,,,,
Phenotypes,Previous history of application site reactions suggestive of allergic contact dermatitis with the rivastigmine patch.,n_627,,,,,,,
Phenotypes,Renal impairment.,n_628,,,,,,,
Phenotypes,Gastric or duodenal ulcers (or susceptibility to ulcers).,n_629,,,,,,,
Phenotypes,Sick sinus syndrome or conduction abnormalities.,n_630,,,,,,,
Phenotypes,History of asthma or COPD.,n_631,,,,,,,
Phenotypes,Bladder outflow obstruction.,n_632,,,,,,,
Phenotypes,"Pre-existing, or a family history of, QT interval prolongation.",n_633,,,,,,,
Phenotypes,Higher risk of developing torsade de pointes,n_634,,,,,,,
Phenotypes,"Hypersensitivity to the active substance or to any of the excipients, including people with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency, or glucose-galactose malabsorption.",n_635,,,,,,,
Phenotypes,Severe hepatic impairment.,n_636,,,,,,,
Phenotypes,Severe renal impairment  memantine hydrochloride should be avoided if the estimated glomerular filtration rate (eGFR) is less than 5 mL/minute/1.73 m簡.,n_637,,,,,,,
Phenotypes,History of convulsions or predisposing factors for epilepsy.,n_638,,,,,,,
Phenotypes,Severe renal impairment,n_639,,,,,,,
Phenotypes,"Central nervous system depression, comatose states.",n_640,,,,,,,
Phenotypes,"Congenital long QT syndrome, history of Torsade de Pointes, QTc interval",n_641,,,,,,,
Phenotypes,"prolongation, concurrent use with drugs that prolong the QT interval, history of",n_642,,,,,,,
Phenotypes,"ventricular arrhythmias, recent myocardial infarction, uncompensated heart failure.",n_643,,,,,,,
Phenotypes,Uncorrected hypokalaemia.,n_644,,,,,,,
Phenotypes,Progressive supranuclear palsy.,n_645,,,,,,,
Phenotypes,Dementia with Lewy bodies.,n_646,,,,,,,
Phenotypes,Parkinson's disease.,n_647,,,,,,,
Phenotypes,Blood dyscrasias.,n_648,,,,,,,
Phenotypes,"Cardiovascular disease  an ECG may be required, particularly if physical examination identifies cardiovascular risk factors, personal history of cardiovascular disease.",n_649,,,,,,,
Phenotypes,Conditions predisposing to seizures.,n_650,,,,,,,
Phenotypes,Depression.,n_651,,,,,,,
Phenotypes,Diabetes (may raise blood glucose).,n_652,,,,,,,
Phenotypes,Epilepsy.,n_653,,,,,,,
Phenotypes,History of jaundice.,n_654,,,,,,,
Phenotypes,Myasthenia gravis.,n_655,,,,,,,
Phenotypes,Parkinson宎s disease (may be exacerbated).,n_656,,,,,,,
Phenotypes,Photosensitization (may occur with higher dosages).,n_657,,,,,,,
Phenotypes,Prostatic hypertrophy.,n_658,,,,,,,
Phenotypes,Severe respiratory disease.,n_659,,,,,,,
Phenotypes,Susceptibility to angle-closure glaucoma,n_660,,,,,,,
Phenotypes,Bradycardia.,n_661,,,,,,,
Phenotypes,Uncorrected electrolyte disturbances.,n_662,,,,,,,
Phenotypes,Family history of QTc-interval prolongation.,n_663,,,,,,,
Phenotypes,History of heavy alcohol exposure.,n_664,,,,,,,
Phenotypes,Hyperthyroidism.,n_665,,,,,,,
Phenotypes,Hypotension (including orthostatic hypotension).,n_666,,,,,,,
Phenotypes,Prolactin-dependent tumours.,n_667,,,,,,,
Phenotypes,Prolactinaemia.,n_668,,,,,,,
Phenotypes,Risk factors for stroke.,n_669,,,,,,,
Phenotypes,Hypersensitivity to risperidone or to any of the excipients.,n_670,,,,,,,
Phenotypes,Acute porphyrias.,n_671,,,,,,,
Phenotypes,Cataract surgery (risk of intra-operative floppy iris syndrome).,n_672,,,,,,,
Phenotypes,Dehydration.,n_673,,,,,,,
Monitoring,Weight monthly,n_674,,,,,,,
Duration,4-6 week,n_675,,,,,,,
Dosage,Donepezil 5-10 mg/day,n_676,,,,,,,
Dosage,Rivastigmine 1.5-6mg/day*2,n_677,,,,,,,
Treatment,Galantamine  Treatment (NICE),n_678,,,,,,,
Dosage,Galantamine 4mg/day*2,n_679,,,,,,,
Dosage,Memantine 5-20mg/day,n_680,,,,,,,
SideEffect,decreased appetite,n_681,,,,,,,
SideEffect,Depressed,n_682,,,,,,,
SideEffect,Weight lose,n_683,,,,,,,
SideEffect,Hallucination,n_684,,,,,,,
SideEffect,Myalgia,n_685,,,,,,,
Phenotypes,"Difficulties with instrumental activities of daily living (e.g. housework, managing money).",n_686,,,,,,,
Phenotypes,"Difficulties with basic activities of daily living (e.g. feeding,dressing).",n_687,,,,,,,
Phenotypes,Fully dependent,n_688,,,,,,,
Evidence,Moderate to Low quality,n_689,,,,,,,
Duration,12-24 week,n_690,,,,,,,
Population,Mild to Severe Alzheimer's Disease (MMSE 0-26) (ADAS-Cog),n_691,,,,,,,
Duration,26 week,n_692,,,,,,,
Dosage,Rivastigmine,n_693,,,,,,,
Duration,Rivastigmine,n_694,,,,,,,
Population,Rivastigmine,n_695,,,,,,,
Treatment,Rivastigmine,n_696,,,,,,,
SideEffect,Rivastigmine,n_697,,,,,,,
Therapy,Rivastigmine,n_698,,,,,,,
Effectiveness,Rivastigmine,n_699,,,,,,,
Evidence,Rivastigmine,n_700,,,,,,,
Step,Rivastigmine,n_701,,,,,,,
Phenotypes,Rivastigmine,n_702,,,,,,,
THERAPY_EFFECTIVENESS,Rivastigmine,n_703,,,,,,,
Population,Mild to moderate Alzheimer's Disease (MMSE 10-26),n_704,,,,,,,
Dosage,Memantine 20 mg/day,n_705,,,,,,,
Dosage,Memantine 28 mg/day,n_706,,,,,,,
Evidence,Low quality (Level C),n_707,,,,,,,
Effectiveness,attenuates worsening of physical function and activities of daily living,n_708,,,,,,,
Effectiveness,"improving BPSD, including anxiety",n_709,,,,,,,
Treatment,Suvorexant,n_710,,,,,,,
Treatment,Donepezil Treatment (Alzheimer Society of B.C.),n_711,,,,,,,
Treatment,Memantine Treatment (Alzheimer Society of B.C.),n_712,,,,,,,
Phenotypes,memory loss,n_713,,,,,,,
Phenotypes,cognitive ability loss,n_714,,,,,,,
Phenotypes,Difficultly coming up with the right word or name.,n_715,,,,,,,
Phenotypes,Difficultly remembering names when introduced to new people.,n_716,,,,,,,
Phenotypes,Having difficulty performing tasks in social or work settings.,n_717,,,,,,,
Phenotypes,Forgetting material that was just read.,n_718,,,,,,,
Phenotypes,Losing or misplacing a valuable object.,n_719,,,,,,,
Phenotypes,Experiencing increased trouble with planning or organizing.,n_720,,,,,,,
Phenotypes,Being forgetful of events or personal history.,n_721,,,,,,,
Phenotypes,"Feeling moody or withdrawn, especially in socially or mentally challenging situations.",n_722,,,,,,,
Phenotypes,"Being unable to recall information about themselves like their address or telephone number, and the high school or college they attended.",n_723,,,,,,,
Phenotypes,Experiencing confusion about where they are or what day it is.,n_724,,,,,,,
Phenotypes,Requiring help choosing proper clothing for the season or the occasion.,n_725,,,,,,,
Phenotypes,Having trouble controlling their bladder and bowels.,n_726,,,,,,,
Phenotypes,"Experiencing changes in sleep patterns, such as sleeping during the day and becoming restless at night.",n_727,,,,,,,
Phenotypes,Showing an increased tendency to wander and become lost.,n_728,,,,,,,
Phenotypes,"Demonstrating personality and behavioral changes, including suspiciousness and delusions or compulsive, repetitive behavior like hand-wringing or tissue shredding.",n_729,,,,,,,
Phenotypes,Require around-the-clock assistance with daily personal care.,n_730,,,,,,,
Phenotypes,Lose awareness of recent experiences as well as of their surroundings.,n_731,,,,,,,
Phenotypes,"Experience changes in physical abilities, including walking, sitting and, eventually, swallowing",n_732,,,,,,,
Phenotypes,Have difficulty communicating.,n_733,,,,,,,
Phenotypes,"Become vulnerable to infections, especially pneumonia.",n_734,,,,,,,
Population,MCI to Mild Alzheimer's Disease,n_735,,,,,,,
Population,Mild to severe Alzheimer's Disease,n_736,,,,,,,
Population,Mild to moderate Alzheimer's Disease,n_737,,,,,,,
Population,Moderate to severe Alzheimer's Disease,n_738,,,,,,,
Population,Agitation associated with dementia due to Alzheimer's disease,n_739,,,,,,,
Population,Insomnia,n_740,,,,,,,
SideEffect,ARIA,n_741,,,,,,,
SideEffect,headache,n_742,,,,,,,
SideEffect,Infusion-related reactions,n_743,,,,,,,
SideEffect,Loss of appetite,n_744,,,,,,,
SideEffect,Increased frequency of bowel movements,n_745,,,,,,,
SideEffect,Sleepiness,n_746,,,,,,,
SideEffect,Common cold symptoms,n_747,,,,,,,
SideEffect,Restlessness or feeling like  need to move,n_748,,,,,,,
SideEffect,Impaired alertness and motor coordination,n_749,,,,,,,
SideEffect,Worsening of depression or suicidal thinking,n_750,,,,,,,
SideEffect,Complex sleep behaviors,n_751,,,,,,,
SideEffect,Sleep paralysis,n_752,,,,,,,
SideEffect,Compromised respiratory function,n_753,,,,,,,
Therapy,Maintain regular times for meals and for going to bed and getting up,n_754,,,,,,,
Therapy,Seek morning sunlight exposure,n_755,,,,,,,
Therapy,"Encourage regular daily exercise, but no later than four hours before bedtime",n_756,,,,,,,
Therapy,"Avoid alcohol, caffeine and nicotine",n_757,,,,,,,
Therapy,Treat any pain,n_758,,,,,,,
Therapy,"If the person is taking a cholinesterase inhibitor (tacrine, donepezil, rivastigmine or galantamine), avoid giving the medicine before bed",n_759,,,,,,,
Therapy,Make sure the bedroom temperature is comfortable,n_760,,,,,,,
Therapy,Provide nightlights and security objects,n_761,,,,,,,
Therapy,"If the person awakens, discourage staying in bed while awake; use the bed only for sleep",n_762,,,,,,,
Therapy,Discourage watching television during periods of wakefulness,n_763,,,,,,,
Symptom,Memory loss for recent events,n_764,,,,,,,
Symptom,Difficulty learning new information,n_765,,,,,,,
Symptom,Subtle language problems,n_766,,,,,,,
Symptom,Significant memory loss,n_767,,,,,,,
Symptom,Confusion in daily activities,n_768,,,,,,,
Symptom,Behavioral changes,n_769,,,,,,,
Symptom,Severe memory loss,n_770,,,,,,,
Symptom,Complete dependence on others,n_771,,,,,,,
Symptom,Physical symptoms,n_772,,,,,,,
Effectiveness,small significant benefit on cognitive function and ADL,n_773,,,,,,,
Duration,Review every 6 months,n_774,,,,,,,
Effectiveness,significant effect on ADL function at 24 weeks,n_775,,,,,,,
Duration,2 weeks,n_776,,,,,,,
SideEffect,Gastrointestinal,n_777,,,,,,,
SideEffect,Falls,n_778,,,,,,,
Condition,Severe renal impairment,n_779,,,,,,,
Monitoring,Cognitive function (MMSE) every 6 months,n_780,,,,,,,
source,es_20,es_20,,,,,,,
source,es_19,es_19,,,,,,,
source,es_18,es_18,,,,,,,
source,es_1,es_1,,,,,,,
source,es_22,es_22,,,,,,,
source,es_2,es_2,,,,,,,
source,es_17,es_17,,,,,,,
source,es_3,es_3,,,,,,,
source,es_4,es_4,,,,,,,
source,es_5,es_5,,,,,,,
source,es_14,es_14,,,,,,,
source,es_10,es_10,,,,,,,
source,es_11,es_11,,,,,,,
source,es_12,es_12,,,,,,,
source,es_7,es_7,,,,,,,
source,es_16,es_16,,,,,,,
source,es_6,es_6,,,,,,,
source,es_15,es_15,,,,,,,
source,es_8,es_8,,,,,,,
source,es_9,es_9,,,,,,,
source,es_13,es_13,,,,,,,
source,es_21,es_21,,,,,,,
source,MONDO,s_1,PrimeKG,MONDO,,,,,
source,MONDO_grouped,s_2,PrimeKG,MONDO_grouped,,,,,
source,REACTOME,s_3,PrimeKG,REACTOME,,,,,
source,National Institute for Health and Care Excellence,s_4,PrimeKG,National Institute for Health and Care Excellence,,,,,
source,成功大學,s_5,PrimeKG,成功大學,,,,,
source,Ministry of Health Malaysia,s_6,PrimeKG,Ministry of Health Malaysia,,,,,
source,American Academy of Family Physicians,s_7,PrimeKG,American Academy of Family Physicians,,,,,
source,臺中榮總,s_8,PrimeKG,臺中榮總,,,,,
source,Alzheimer Society,s_9,PrimeKG,Alzheimer Society,,,,,
source,Japanese Society of Neurology,s_10,PrimeKG,Japanese Society of Neurology,,,,,
source,Alzheimer's Association,s_11,PrimeKG,Alzheimer's Association,,,,,
source,The Association of Scientific Medical Societies in Germany,s_12,PrimeKG,The Association of Scientific Medical Societies in Germany,,,,,
source,Cognitive Decline Partnership Centre,s_13,PrimeKG,Cognitive Decline Partnership Centre,,,,,
source,HPO,s_14,PrimeKG,HPO,,,,,
source,DrugBank,s_15,PrimeKG,DrugBank,,,,,
source,NCBI,s_16,PrimeKG,NCBI,,,,,
source,CTD,s_17,PrimeKG,CTD,,,,,
source,EMC,s_18,PrimeKG,EMC,,,,,
source,Cochrane Library,s_19,PrimeKG,Cochrane Library,,,,,
source,JAMA,s_20,PrimeKG,JAMA,,,,,
source,Cocharne Library,s_21,PrimeKG,Cocharne Library,,,,,
source,IJN,s_22,PrimeKG,IJN,,,,,
source,pubmed,s_23,PrimeKG,pubmed,,,,,
